Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA
August 21, 2015 at 12:03 PM EDT
Sarepta receives rare pediatric disease designation from FDA for Eteplirsen to tread duchenne muscular dystrophy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.